Insmed Incorporated
Commercial biopharma focused on serious respiratory and rare diseases, led by BRINSUPRI and ARIKAYCE with additional Phase 3 pulmonary programs.
Respiratory & rare disease · Small molecules, inhaled therapies & gene therapy · Commercial + Phase 3